PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES FOR MEDICATIONS DEVELOPMENT. POP: 9/20/2017-9/19/2022. N01DA-17-8935.

药物开发的药代动力学和药效动力学研究。

• 批准号: 10038836
• 负责人: ELIZABETH POLVENT
• 金额: $ 133.42万
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-20 至 2022-09-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10038836
• 关键词: Biological Products; Cannabidiol; Clinical Pharmacology; Contractor; Development; Disease; Drug Interactions; Drug Kinetics; Enzymes; Molecular; Monoclonal Antibodies; Morphine; Pharmaceutical Preparations; Phase; Tobacco use; United States Food and Drug Administration; Vaccines; cocaine use; marijuana use; methamphetamine use; novel therapeutics; opioid abuse; opioid use; pharmacokinetics and pharmacodynamics; stem

Contractor shall carry out clinical pharmacology/pharmacokinetic studies to support the development of new medications for the treatment of disorders stemming from tobacco, cannabis, cocaine, methamphetamine, or opiate use or abuse. The study medications include new molecular entities, new biological products (monoclonal antibodies, enzymes, vaccines, etc.), new drug products, and drug products approved by the Food and Drug Administration (FDA) for other indications.

承包商应开展临床药理学/药代动力学研究，以支持开发用于治疗烟草、大麻、可卡因、甲基苯丙胺或阿片类药物使用或滥用引起的疾病的新药。研究药物包括新分子实体、新生物制品（单克隆抗体、酶、疫苗等），新的药物产品，以及美国食品药品监督管理局（FDA）批准用于其他适应症的药物产品。